Several clinical trials are in progress (Table 4), including those that evaluate CAR T cells that target CD171 [113] in patients with NB and ganglioneuroblastoma (NCT02311621) or B7H3 (NCT04483778) in relapsed/refractory pediatric solid tumors. Here, CD276 is linked to neuroblastoma.